Incyte INCY TABRECTA Royalty Revenues — Total revenues

Other product segments

Similar metrics at other companies

GERNRoyalties — Total revenues

$66K-60.5%

SUPNRoyalty, licensing, and other revenues — Total revenues

$29.31M+274%

LGNDRoyalties — Total revenues and income

$42.96M+56.3%

NVAXRoyalties — Total Revenue

$3.52M—

LNTHLicenseand Royalty Revenues — Revenue

$7.48M+28.0%

DNTHRoyalty — Revenue

$0—

Questions, answered.

What is Incyte's TABRECTA royalty revenues — total revenues?

Incyte (INCY) reported TABRECTA royalty revenues — total revenues of $5.98M in Q1 2026.

How has Incyte's TABRECTA royalty revenues — total revenues changed year-over-year?

Incyte's TABRECTA royalty revenues — total revenues decreased by 6.7% year-over-year, from $6.41M to $5.98M.

What is the long-term trend for Incyte's TABRECTA royalty revenues — total revenues?

Over 4 years (2021 to 2025), Incyte's TABRECTA royalty revenues — total revenues has grown at a 26.6% compound annual growth rate (CAGR), from $10.39M to $26.7M.

What does TABRECTA royalty revenues — total revenues mean?

This metric represents the total royalty income recognized from the commercialization of a specific oncology therapeutic product. It reflects the contractual percentage of net sales earned by the company from a licensing partner responsible for the product's global distribution and marketing. This revenue stream is a key indicator of the product's market penetration and clinical adoption in the treatment of specific genetic mutations in non-small cell lung cancer.